Show simple item record

dc.contributor.authorRossello, Xavier
dc.contributor.authorRodriguez-Sinovas, Antonio
dc.contributor.authorVilahur, Gemma
dc.contributor.authorCrisóstomo, Verónica
dc.contributor.authorJorge, Inmaculada
dc.contributor.authorZaragoza Sánchez, Carlos 
dc.contributor.authorZamorano, José L.
dc.contributor.authorBermejo, Javier
dc.contributor.authorOrdóñez, Antonio
dc.contributor.authorBoscá, Lisardo
dc.contributor.authorVázquez, Jesús
dc.contributor.authorBadimón, Lina
dc.contributor.authorSánchez-Margallo, Francisco M.
dc.contributor.authorFernández-Avilés, Francisco
dc.contributor.authorGarcia-Dorado, David
dc.contributor.authorIbáñez, Borja
dc.date.accessioned2020-01-16T12:28:13Z
dc.date.available2020-01-16T12:28:13Z
dc.date.issued2019
dc.identifier.issn2045-2322spa
dc.identifier.urihttp://hdl.handle.net/10641/1807
dc.description.abstractDespite many cardioprotective interventions have shown to protect the heart against ischemia/ reperfusion injury in the experimental setting, only few of them have succeeded in translating their findings into positive proof-of-concept clinical trials. Controversial and inconsistent experimental and clinical evidence supports the urgency of a disruptive paradigm shift for testing cardioprotective therapies. There is a need to evaluate experimental reproducibility before stepping into the clinical arena. The CIBERCV (acronym for Spanish network-center for cardiovascular biomedical research) has set up the “Cardioprotection Large Animal Platform” (CIBER-CLAP) to perform experimental studies testing the efficacy and reproducibility of promising cardioprotective interventions based on a prespecified design and protocols, randomization, blinding assessment and other robust methodological features. Our first randomized, control-group, open-label blinded endpoint experimental trial assessing local ischemic preconditioning (IPC) in a pig model of acute myocardial infarction (n = 87) will be carried out in three separate sets of experiments performed in parallel by three laboratories. Each set aims to assess: (A) CMR-based outcomes; (B) histopathological-based outcomes; and (C) protein-based outcomes. Three core labs will assess outcomes in a blinded fashion (CMR imaging, histopathology and proteomics) and 2 methodological core labs will conduct the randomization and statistical analysis.spa
dc.language.isoengspa
dc.publisherScientific Reportsspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.titleCIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions.spa
dc.typearticlespa
dc.description.versionpost-printspa
dc.rights.accessRightsopenAccessspa
dc.description.extent1525 KBspa
dc.identifier.doi10.1038/s41598-019-56613-6spa
dc.relation.publisherversionhttps://www.nature.com/articles/s41598-019-56613-6spa


Files in this item

FilesSizeFormatView
CiberClap. A multicenter precl ...1.489MbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España